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RESEARCH ARTICLE

Imaging acute effects of bevacizumab on tumor vascular
kinetics in a preclinical orthotopic model of U251 glioma
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| Kelly A. Keenan1 |

The effect of a human vascular endothelial growth factor antibody on the vasculature
of human tumor grown in rat brain was studied. Using dynamic contrast-enhanced
magnetic resonance imaging, the effects of intravenous bevacizumab (Avastin;
10 mg/kg) were examined before and at postadministration times of 1, 2, 4, 8,
12 and 24 h (N = 26; 4–5 per time point) in a rat model of orthotopic, U251 glioblastoma (GBM). The commonly estimated vascular parameters for an MR contrast agent
were: (i) plasma distribution volume (vp), (ii) forward volumetric transfer constant
(Ktrans) and (iii) reverse transfer constant (kep). In addition, extracellular distribution
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volume (VD) was estimated in the tumor (VD-tumor), tumor edge (VD-edge) and the
mostly normal tumor periphery (VD-peri), along with tumor blood flow (TBF), peritumoral hydraulic conductivity (K) and interstitial flow (Flux) and tumor interstitial
fluid pressure (TIFP). Studied as % changes from baseline, the 2-h post-treatment
time point began showing significant decreases in vp, VD-tumor, VD-edge and VD-peri, as
well as K, with these changes persisting at 4 and 8 h in vp, K, VD-tumor,
trans

(t-tests; p < 0.05–0.01). Decreases in K

−edge

and

-peri

were observed at the 2- and 4-h time

points (p < 0.05), while interstitial volume fraction (ve; = Ktrans/kep) showed a significant decrease only at the 2-h time point (p < 0.05). Sustained decreases in Flux were
observed from 2 to 24 h (p < 0.01) while TBF and TIFP showed delayed responses,
increases in the former at 12 and 24 h and a decrease in the latter only at 12 h. These
imaging biomarkers of tumor vascular kinetics describe the short-term temporal
changes in physical spaces and fluid flows in a model of GBM after Avastin
administration.
KEYWORDS

Avastin, DCE-MRI, distribution volume, GBM, Ktrans, Magnevist, peri-tumoral fluid flow, rat,
tumor interstitial fluid pressure

Abbreviations used: 2GE, dual-echo gradient-echo; ANCOVA, analysis of covariance; ASL, arterial spin labeling; DCE-MRI, dynamic contrast-enhanced MRI; FDA, US Food and Drug
Administration; Flux, peri-tumoral interstitial flow; GBM, glioblastoma; H&E, hematoxylin and eosin; K, hydraulic conductivity; kep, reverse transfer constant;; Ktrans, forward volumetric transfer
constant; LL, Look-Locker; MRCA, magnetic resonance contrast agent; NA, number of averages; NE, number of echoes; OS, overall survival; PFS, progression-free survival; ROI, region of
interest; RTOG, Radiation Therapy Oncology Group; TBF, tumor blood flow; TIFP, tumor interstitial fluid pressure; TME, tumor microenvironment; VD, extracellular distribution volume; ve,
interstitial volume fraction; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; vp, plasma distribution volume.
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We studied rat cerebral tumor xenografts of a human glioblastoma (GBM) cell line before, and in the hours after, administration of the human
vascular endothelial growth factor (VEGF) antibody, Avastin (Genentech Inc., South San Francisco, CA, USA). Significant changes in the state of
the vasculature and tumor microenvironment (TME) were observed in the short term (hours) after administration. Avastin does not affect the rat
cerebrovascular system,1 and thus the result demonstrated an early response in the isolated tumor vascular system. A broad spectrum of
parameters was estimated: tumor blood flow (TBF), the forward volumetric transfer constant (Ktrans), the extravascular extracellular space (ve),
plasma volume (vp), the extracellular space (also known as the distribution volume [VD]), Flux, tumor interstitial fluid pressure (TIFP), and VD in the
mostly normal tissue outside the rim of the tumor. These generated a description of the physical spaces and fluid flows in the tumor and its
immediate surround, in the tumor at rest, and after a significant perturbation.
Avastin, a nonselective, recombinant humanized monoclonal antibody effectively blocks the actions of VEGF,2–4 and is often used to
supplement chemotherapy and radiotherapy in cancer clinical treatments. Avastin received accelerated approval by the US Food and Drug
Administration (FDA) for the treatment of recurrent GBM in 2009 vis-à-vis the BRAIN trial (A Study to Evaluate Bevacizumab Alone or in
Combination with Irinotecan for Treatment of Glioblastoma Multiforme).5 Experimental data and clinical trials supported its use in controlling
glioma size and/or brain edema.6,7 Avastin was expected to improve survival and quality of life in patients with GBM, compared with current
protocols. However, two major studies, AVAglio8 and the Radiation Therapy Oncology Group (RTOG)9 clinical trials, failed to demonstrate
additional benefits of Avastin in newly diagnosed GBM. Another recently concluded trial (EORTC26101) that tested Avastin in combination with
Lomustine also reported similar results.10 Despite limitations, hope that Avastin improves patient outcomes continues, as does its use in cancer
therapy, including for GBM.11,12
Pharmacologically, Avastin binds the human VEGF-A isoform and inhibits its downstream effects on vascular permeability and
neovascularization via VEGF receptor (VEGFR)-1, -2 and -3–mediated actions.13 In the long term, Avastin induces vascular pruning, decreases
tumor growth and may eventually lead to tumor shrinkage.14 In the short term, VEGF inhibition increases tumor perfusion and decreases vascular
permeability, thus inducing a hydrostatic pressure gradient across the vascular wall (decreasing TIFP) that facilitates drug penetration.9,15–18 These
effects are collectively referred to as “vascular normalization”,19 and are suggested to make concurrent radiotherapy and chemotherapy more
efficient by increasing tumor oxygenation and drug delivery, respectively.20–22 In planning this study, we reasoned that vascular normalization,
since it affects TIFP, should be accompanied by a spectrum of fluid-mechanical changes in the TME. Accordingly, physical estimates of spaces,
flows and fluxes were planned via DCE-MRI experiments.
As noted, Avastin does not bind to the murine equivalent of VEGF-A.1 This might be seen as a limitation in studying vascular physiology in
tumor models, but in murine xenografts with implanted human tumors, it offers a unique opportunity to isolate the effect of Avastin on the tumor
vasculature itself.
Both retrospective6,7,23–25 and prospective26–28 approaches have examined tumor status and vascular function in GBM after VEGF inhibition
by Avastin. These studies reported effects of Avastin following multiple injections over several days or weeks and showed an attenuation of
vascular permeability, and an accompanying decrease in brain edema and tumor volume in patients. However, the literature is lacking in reports of
Avastin's effects on tumor vasculature shortly after administration. We report herein the effects of Avastin on a model of human brain tumor
vascular physiology in the first few hours after intravenous (iv) administration. An athymic, immune-compromised rat model of orthotopic U251
glioblastoma xenograft was used in conjunction with repeated DCE-MRI measures to assess the tumor vasculature and TME before and after
Avastin treatment. The effect of Avastin reported herein on vascular parameters, physical spaces and fluid flows is presumed to be a result of a
direct effect on the VEGF produced by the human tumor, rather than an indirect effect on the rat vasculature.

2

MATERIALS AND METHODS

|

Avastin (bevacizumab) was a kind gift from Genentech Inc. All the other materials used were of pharmaceutical or analytical grade.

2.1

|

U251 rat model of orthotopic glioma

All experimental procedures were approved by the Institutional Animal Care and Use Committee (protocol IACUC #1388). Adult female, immunecompromised, RNU/RNU rats (n = 29) were intracerebrally implanted as follows: animals were anesthetized with isoflurane (4% for induction,
1.5% to 2.0% for maintenance, balance N2O:O2 = 2:1). The scalp was swabbed with Betadine and alcohol, the eyes coated with Lacri-lube and the
head immobilized in a small animal stereotactic device (Kopf, Cayunga, CA, USA). After draping, a 1 cm incision was made 2 mm right of the midline and the skull exposed. A burr hole was drilled 3.5 mm to the right of bregma, without penetrating the dura. A #2701 10-μL Hamilton syringe
with a 26-gauge needle containing freshly harvested U251 tumor cells from log phase growth (5 x 105 cells in 10 μL of PBS) was lowered to a
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depth of 3.0 mm and then raised back up to a depth of 2.5 mm. Cells were injected at a rate of 0.5 μL/10 s until the entire volume was used. The
needle was left in place for 5 min longer then gently withdrawn, the burr hole sealed with sterile bone wax and the scalp sutured.29–33 Rats were
randomly distributed among the different time-treatment cohorts.

2.2

|

MRI studies

Next, 21–24 days after tumor induction, each animal was anesthetized with isoflurane (4% for induction, 0.75% to 1.5% for maintenance, balance
N2O:O2 = 2:1) and allowed to spontaneously respire. A tail vein was cannulated for MRCA administration. Body temperature was maintained at
37 C with warm air and monitored via an intrarectal probe.
All studies were performed using a Varian (Agilent, Santa Clara, CA, USA), 7-T, 20-cm bore magnet and a Bruker console running Paravision
6.0 software. Gradient maximum strength and rise time were 250 mT/m and 120 μs, respectively. Transmit and receive coils included a Bruker
Quadrature Birdcage (transmit) and four-channel phased-array surface coil receiver (Rapid MR International, Columbus, OH, USA). All MRI image
sets were acquired with a 32 mm x 32 mm FOV. Two MRI studies were conducted with an interval of 24 h between the two. Avastin was
administered at 1, 2, 4, 8, 12 or 24 h before the second MRI, thus yielding a study of the postadministration time dependence of tumor
physiology.
To coregister images with postmortem histopathology, high-resolution T1-weighted images were acquired pre- and post-MRCA with the
following parameters: matrix = 256 x 192, 27 slices, 0.5 mm thickness, no gap, number of echoes (NE) = 1, number of averages (NA) = 4, and
TE/TR = 16/800 ms in a spin-echo sequence. TBF was measured by arterial spin labeling (ASL). ASL data were acquired to estimate tumor and
cerebral blood flow in a single central slice.34 Sets of MRI parameters were obtained with alternating gradients and frequency offsets in combinations of four as follows: matrix = 128 x 64, one 2.0-mm slice, NA = 2, TE/TR = 24/1500 ms, arterial labeling = 1 s, and total time = 13 min.
Two Look-Locker (LL) sequences were run to produce voxel-by-voxel maps of tissue T1 prior to, and immediately after, a dual gradient echo
(2GE) DCE-MRI study. LL sequence parameters were as follows: matrix = 128 x 64, five 2.0-mm slices, no gap, NE = 24 inversion-recovery
echoes, and TR = 2000 ms. The DCE-MRI 2GE sequence that was run between the paired LL acquisitions had the following parameters:
150 acquisitions at 4.0-s intervals, matrix = 128 x 64, three 2.0-mm slices, no gap, flip angle = 27 , NE = 2, NA = 1, TE = 2.0, 4.0 ms, TR = 60 ms,
and SW = 150 kHz. The slice positioning was matched for the DCE-MRI and LL sequences. The bolus MRCA (Magnevist, Bayer Healthcare
Pharmaceuticals, Wayne, NJ, USA) injection was performed by hand push at image 15. The total MR run time was 10 min.

2.3

|

Drug administration

Avastin was injected as a single 30-min iv infusion at a dose of 10 mg/kg in a volume of 1.0 mL. Following drug administration, depending on the
group assignment for each rat, the second imaging session was conducted at 1, 2, 4, 8, 12 or 24 h post-treatment (please see the flowchart in the
supporting information). Since the 24-h test–retest behavior of vascular estimates in our DCE-MRI studies has been studied,29 this had the effect
of providing a temporal record of changes in vascular parameters at 1 to 24 h after the administration of Avastin. This protocol has been
conducted in multiple studies published by our group.29–33,35–38

2.4

|

Data analysis

DCE-MRI brain tumor studies contain varying amounts of information, depending (among other things) on whether or not the blood–brain barrier
has been breached in a particular voxel. In the central mass of many brain tumors, the microvasculature is abnormal and quite permeable to the
MRCA, while in normal brain, the microvasculature is impermeable to those agents. Thus, to produce stable estimates of model parameters, the
data should be queried voxel-by-voxel as to which model best describes the temporal behavior of the data. We have employed a data-driven
analytical approach that, among the pharmacokinetic models employed, identifies the model that best balances bias and variance.39–41 This
approach generally produces stable estimates of those vascular parameters available to the model chosen. While seldom employed in DCE-MRI
studies, such an approach is part of the standard toolkit of physical scientists and applied mathematicians.42,43
The long history of pharmacokinetic studies using radioactive tracers has provided a number of widely used models that predate even the
earliest MRI study designed to estimate vascular parameters.44 These earlier approaches, particularly the Patlak,45 revised Patlak46
(mathematically identical to the extended Tofts model)47 and the Logan48 models, are suitable for the analysis of DCE-MRI. Notably, two of them
(the Patlak and Logan models) rely on the linearization of temporally varying data for model confirmation, and the third (the revised Patlak model)
can be linearized.39–41 This allows the inspection of plotted data to confirm the appropriateness of the model for the available data. For examples
of linearization of DCE-MRI data, see Figure S1 for a Patlak plot and an extended Patlak plot, and Figure S2 for a Logan plot.
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As noted, there are a variety of conditions in the tissue under study. In normal tissue, the vasculature is not permeable to contrast agents of
any size. In that case, only the plasma volume of the vasculature, vp, can be estimated. In other tissue, for instance in ischemic tissue, a slow
leakage of the contrast agent from the vasculature to the interstitial space can be measured, allowing both vp and the forward volumetric transfer
constant, Ktrans, to be estimated from a record of contrast versus time.34 Finally, in typical tumors studied with light contrast agents, an approach
to equilibration between the plasma concentration and the extravascular concentration can be observed, allowing vp, Ktrans, and the reverse
transfer constant, kep, to be estimated. In this latter case, the extracellular, extravascular volume fraction, ve, can be calculated as the ratio
trans

ve = Kkep . The three nested models that accomplish these estimates are here called Model 1, Model 2 and Model 3. Model 2 and Model 3 employ
the Patlak and Standard models (see the supporting information). In the process of constructing the three models, they are compared with one
another, and the model that best balances variance and bias is chosen. In typical data, a map of model selection serves to delineate not only which
model is best, but, because of the vascular physiology of cerebral tumors, where the tumor mass is in the DCE-MRI images.39–41 In this paper, for
each animal, the means of the parameters Ktrans, ve and vp in the Model 3 region corresponding to the tumor are reported as summary measures
of tumor vascular parameters.
We followed published conventions that describe peri-tumoral MRCA/exudate flow estimation techniques in embedded brain tumors to
demarcate the tumor_edge and _periphery.33 Tumor rim was the last set of pixels that circumscribed the tumor inner border as determined by
comparing the DCE-MRI maps with its own postcontrast T1-weighted image and the H&E histology. The tumor periphery is the immediate set of
pixels surrounding the tumor border that constitutes the peri-tumoral normal brain region where the contrast agent is presumed to flow outward
without vascular resorption.
In regions with a measurable kep, an equilibration between the extravascular and intravascular contrast agent concentrations will eventually
take place. Usually, in our experience, this equilibration is approached during the latter half of the 10-min DCE-MRI study. For almost all MRI
contrast agents, there is little or no affinity between the agent and intravascular or extravascular elements; the binding potentials are close to
zero. (But note that gadofosveset does bind to serum albumin, and possibly also to extravascular sites49,50). In the absence of binding, a Logan plot
of DCE-MRI data will eventually linearize (Figure S2). Assuming no uptake by living cells, the linear part of the Logan plot will have a slope that
estimates the entire extracellular volume fraction; this parameter is called the distribution volume, VD. Note that, formally, VD = ve+vp, and in our
studies, these two estimates do not disagree,29 but because it is one of only two parameters to be estimated, rather than the three of Model
3, VD is usually a more stable point estimate than the sum of ve and vp. In this paper, for each animal, the mean of the parameter VD in the Model
3 region is reported as a summary measure, VD-tumor. In addition, the mean of the distribution volume in an ROI consisting of the outer rim of
voxels in the Model 3 region is reported as VD-edge. We consider the latter an important parameter because it gives a measure of the volume
occupied by the cellular fraction in the rapidly growing rim of the tumor,29 allows the estimation of TIFP,35 and is an important aspect of
mechanical modeling of tumor stresses and fluxes. Because vp is typically quite small, distribution volumes approximate porosities and, as noted,
are generally more stable than estimates of ve; these measures can be used to estimate the fluid conductivity, K, of the tumor,35 and via Darcy's
law, the tumor interstitial fluid pressure.
Finally, in the analysis of DCE-MRI studies, a novel extension of both Patlak and Logan approaches to DCE-MRI modeling allows the estimation of VD-peri, the distribution volume in the mostly normal tissue surrounding the Model 3 tumor region, and the tumor exudate/intersitial flow
(Flux) across the boundary between the tumor and its normal surround.33 VD-peri and Flux are highly correlated, are important aspects of mechanical modeling of tumor stresses and fluxes, and are themselves signals of changes in the physiology of the tumor (because of changes in tumor
mechanical stresses and fluid pressures) when the tumor is confronted with therapeutic challenges.
To complete the array of measures of tumor physiology, a single-slice arterial spin-labeling experiment was conducted. The mean estimate of
TBF in the Model 3 region was employed as a measure of changes in tumor physiology after the administration of Avastin.
In summary, for the tumor in the Model 3 region, we have estimates of Ktrans, vp, ve, VD-tumor, VD-edge, VD-peri, Flux, K, TIFP and TBF, before
and after the administration of Avastin (please refer to the supporting information for details).

2.5

|

Histology

After the second MRI study, the animals were continued on isoflurane anesthesia and transcardially perfused with normal saline followed by
buffered 4% paraformaldehyde. The brains were carefully removed and stored in fixative overnight at 4 C. Two-millimeter thick coronal slices
through the tumor were obtained using a rat-brain matrix (Activational Systems, Inc., Warren, MI, USA). The brain tissue was processed using a
VIP Tissue Tek Processing center and embedded in paraffin. Seven-micrometer thick sections were cut from the paraffin block corresponding to
the selected MR imaging slices and placed on Superfrost Plus (Fisher Scientific, Waltham, MA, USA) slides. These sections contained the largest
tumor area and were stained with H&E after dehydration and rehydration in an ethanol series for evaluation of tumor ROIs.30 The slides were
scanned at 20X magnification in a Leica Aperio CS2 bright field illumination scanner (Leica Biosystems Inc., Buffalo Grove, IL, USA). Images were
collected using Aperio ImageScope software. Brain sections from another batch of U251 tumor-bearing rats untreated with Avastin were used to
immunostain for VEGF expression.
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Statistical analysis

There were 29 animals across six time points. Three animals were not included in the final analyses due to technical problems during imaging. In
the final analysis, there were four animals in each of the 1-, 4-, 12- and 24-h groups and five each in the 2- and 8-h time points. For each animal,
MRI parameters were estimated before (pre) and after (post) drug administration for a given ROI, with the timing of the second measurement
depending upon the group assignment for each animal. The outcome of interest for each parameter was the % change between the pre- and
Pre−Post
Pre− Post
post-Avastin parameters. Percentage changes were calculated for each animal as 100 Pre
+ Post , rather than the usual 100 Pre , where Pre is the

value of the parameter in the first study, and Post is its value in the second study, postadministration. Because this preserves the null hypothesis
that the Pre and Post samples are drawn from the same distribution, this has the effect of removing a source of bias in the presentation of results.
Mean and standard deviations of the parameter % changes for the animals in each time point were computed, along with the % change for each
parameter in this manner.
SAS version 9.4 was used to perform all data analyses. t-tests were performed to test whether the % change was equal to zero for each time
point (1, 2, 4, 8, 12 and 24 h after drug administration). The testing level was set at 0.05 for these comparisons. Analysis of covariance (ANCOVA),
testing the % changes among the time points while adjusting for predrug administration measurements, was used to assess the differences in the
% changes for the parameters among the time points. If the overall difference was significant, additional pairwise comparisons of the time points
were performed. The testing level for the overall difference was set at 0.05. For the pairwise comparisons, the testing level was set at 0.01 to
account for multiple comparisons.

3

|

RESULTS

At the time of imaging, average tumor diameter on a coronal image was about 4 mm at its largest extent. Data from the pretreatment imaging
sessions presented a typical space-occupying tumor with mass effects, as seen in human GBMs, but, unlike human GBMs, with limited infiltration.
Central tumor enhancement was observed, and in all cases was associated with peri-tumoral edema flow. In several cases, mass effect, with
midline shift and occasional compression of ventricles, was observed. The extent of tumor borders observed on imaging during post-treatment
MRI was matched by their corresponding H&E-stained sections. A set of T1 images along with its corresponding TBF map, model selection map
and H&E-stained brain section from one rat are shown in Figure 1. Figure 2 shows an example of pre- and post-treatment parameter maps from a
study conducted 1 h after the administration of Avastin, where no significant effects of the treatment on measured vascular parameters were
observed. Parameter values from the two imaging sessions along with their respective % changes and images from VEGF-immunostained brain
sections are provided in the supporting information.
Figure 3 illustrates an experiment from the 4-h time point, wherein several DCE-MRI measured parameters were affected. Temporal changes
in TBF, Ktrans, Flux and the parameter that summarizes their collective effect (i.e. TIFP), are presented in Figure 4. A trend towards increased TBF
between 4 and 8 h after treatment was followed by a statistically significant increase at 12 and 24 h after Avastin administration. At 2 and 4 h
postadministration, changes in Ktrans were significantly lower than zero. As to Flux, all but the 1-h time point had changes significantly lower than
zero, whereas TIFP measures were significantly decreased only at the 12-h time point.
Changes with time in contrast agent distribution spaces in the tumor are shown in Figure 5. These are vp, VD-tumor and ve. Estimates of
vp were significantly lower 2 to 12 h after Avastin administration. VD-tumor, on the other hand, exhibited significant decreases only at the
2- and 8-h time points. For ve, the % change was significantly lower than zero only at the 2-h time point. Responses of VD-edge and VD-peri,
the extracellular distribution volume of the boundary of the tumor itself, and of the normal tissue transition zone immediately adjacent to the

F I G U R E 1 An example of spatial agreement between MRI parameters and histology in tumor location and distribution. A, T1 postcontrast; B,
tumor blood flow; C, model selection; and D, hematoxylin and eosin (H&E) staining. The color scale bar for blood flow depicts values of 0–
104 mL.min−1 (black to white). Tumor pixels showing model selection: white, Model 3; orange, Model 2
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F I G U R E 2 An example from a 1-h post-Avastin treatment study that showed no significant effects of therapy. The top panel is pretreatment
(A1-D1) and the bottom panel, post-treatment (A2-E). The parameters maps shown from left to right are: postcontrast T1, Ktrans, ve, model
selection and the corresponding hematoxylin and eosin (H&E) stained brain section. Note the relative stable distribution of all parameters
between the two sessions, suggesting that Avastin did not exert significant effects on tumor vasculature and tumor microenvironment at 1 h after
administration. The color scale bars represent the lowest to highest (black to white) values for the different parameters as shown on their
respective maps. For the model map pixels, white is Model 3 acceptance, pink is Model 2 acceptance and yellow is Model 1 acceptance (green is
not a number)

F I G U R E 3 An example from a 4-h post-Avastin treatment study that showed significant effects of therapy. The top panel is pre-treatment
(A1-D1) and the bottom panel, post-treatment (A2-E). The parameter maps shown from left to right are: postcontrast T1, Ktrans, ve, model
selection and the corresponding hematoxylin and eosin (H&E) stained brain section. Note the decrease in the distribution of Model 3 voxels in
tumor tissue (right hemisphere) from pretreatment to post-treatment maps indicative of effects of Avastin on tumor microenvironment at this
time point. The color scale bars represent the lowest to highest (black to white) values for the different parameters as shown on their respective
maps. For the model map pixels, white is Model 3 acceptance, orange is Model 2 acceptance and yellow is Model 1 acceptance (green is not a
number)

F I G U R E 4 Tumor fluid flows and fluxes. A graph of changes in
cerebral blood flow (CBF), blood-to-brain forward volumetric transfer
constant (Ktrans), tumor interstitial fluid pressure (TIFP) and peri-tumoral
interstitial fluid flow (Flux) at times after Avastin (10 mg/kg; iv)
treatment. The values are plotted as mean ± standard error of the mean
% differences between the pre- and post-treatment values. Asterisks
represent significant difference, p < 0.05
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F I G U R E 5 Tumor distribution spaces. A graph of changes in plasma
distribution volume (vp), MRCA extracellular distribution volume (VD) and
interstitial volume fraction (ve) at times after Avastin (10 mg/kg; iv)
treatment. The values are plotted as mean ± standard error of the mean
% differences between the pre- and post-treatment values. Asterisks
represent significant difference, p < 0.05

F I G U R E 6 Tumor peripheral spaces. A graph of changes in
extracellular distribution volume in the tumor edge (VD-edge), in the
immediately surrounding normal tissue, VD-peri and in K (hydraulic
conductivity in the tumor periphery) as a function of time after Avastin
(10 mg/kg; iv) treatment. These parameters reflect interactions at the
boundary of the tumor and normal brain. The values are plotted as mean ±
standard error of the mean from the % differences between the pre- and
post-treatment values. Asterisks represent significant difference, p < 0.05

tumor boundary, are shown in Figure 6. They showed significant decreases at 2-, 4-, 8- and 24-h time points for VD-edge and VD-peri
(Figure 6), indicative of possible post-treatment tissue compression in the periphery of the tumor. Somewhat following this trend, K was also
significantly low at 2, 4 and 8 h.
An ANCOVA to test the differences between the different time points for a given parameter showed no consistently significant differences
for most parameters. For Flux, however, the overall difference in the % changes among the time points was significant (p = 0.01), with the 1-h
time point for the average % change being significantly higher than the other five time points (p < 0.01 for all).

4

|

DISCUSSION

This paper describes the timeline of glioblastoma vascular normalization during the first 24 h after a single iv injection of Avastin in a rat GBM
model. Apart from more commonly measured parameters such as TBF, blood volume fraction and vascular permeability, acute changes in such
novel indices of the TME as tumoral and transtumoral distribution spaces, hydraulic conductivity, exudate Flux and TIFP are also reported.
Together, they contribute to a comprehensive picture of the tumor vascular status, and tumor fluid mechanical properties, and its downstream
effects on the TME in an embedded brain tumor. Several of these indices also showed acute responses to Avastin treatment, suggesting their use
as predictive biomarkers.51
After an iv injection at 10 mg/kg, Avastin began to exert effects beginning as early as 2 h after administration in a parameter-dependent manner. Avastin led to decreased Ktrans values at 2 and 4 h, along with concomitant decreases in vp. This decrease in vp persisted with a slight elevation from 4 to 8 h postadministration. The changes in vp were not significantly accompanied by Ktrans lowering at this time point. In agreement
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with known and presumed effects of vascular normalization by Avastin,52 decreased permeability was accompanied by a trend of increasing TBF
values throughout the study (Figure 4). TBF changes were statistically significant at 12 and 24 h following Avastin delivery (Figure 4). Opposing
directions of changes in TBF and Ktrans have also been reported after radiotherapy in this tumor model.31 The slightly longer lasting effects on vp
are consistent with previous reports of relative blood volume being an imaging biomarker of Avastin treatment efficacy.53
We note that in previous work, tumor VEGF-A expression has been reported to modulate the effects of Avastin.54 In that work, two mouse
xenograft models of melanoma were employed, A-07 and R-18 with high and low VEGF-A expression, respectively. Two 5-mg/kg doses of
Avastin were used in a 7-day period and the mice were imaged before and after the second drug dose. The A-07 tumor had higher pretreatment
Ktrans values compared with the R-18 tumor and showed lower Ktrans values after Avastin treatment. The R-18 tumor with low VEGF-A did not
respond to Avastin treatment. The extent of Ktrans reduction in A-07 was progressive from post-treatment Day 3 to Day 7. Comparable with the
present data, no significant changes were reported in ve at any post-treatment time point.54
The 2-, 4- and 8-h time points after Avastin administration also showed decreased peri-tumoral exudate Flux and tumor hydraulic conductivity, K. Flux was very sensitive to treatment, with all but the 1-h time point showing statistically significant decreases after treatment. Several of
these time points also coincided with decreases in VD-edge and -peri, which have been shown previously as predictive of Flux, and imply a coupling
between solid and fluid mechanical effects in the periphery of the tumor.33 A concurrent decrease in TIFP was observed only at 12 h after Avastin
treatment, and continued to be low, but not statistically significant, at 24 h. The distribution volume in the tumor (i.e. tissue compression) is a
strong predictor of TIFP35 as well as tumor perfusion, pointing to a solid and fluid mechanical coupling.
Note that the effects of Avastin treatment in this study may underestimate clinical effects, because it is a humanized antibody active against
VEGF produced by the human U251 cells and not rat stromal VEGF. Supporting this view are data that show orthotopically implanted U251 cells
stain positively for VEGF (supporting information) and previous reports that show the biological effects of bevacizumab in U251 glioma-bearing
animals.55–57 Note also that the extent of reduction in vp at 48 h was about 36% following treatment with a VEGF antibody active against both
human and murine VEGF in a subcutaneous colorectal cancer model.58 By contrast, in the current study, although vp decreased significantly until
8 h after treatment, it subsequently recovered (Figure 5), probably because only tumor-derived human VEGF and not murine VEGF was affected
by the drug.
This investigation, and in particular this set of parametric estimates, was motivated by an interest in the solid and fluid mechanical properties
of cerebral tumors. As in all tumors, the local physical properties of the tissue influence the behavior of the cells59,60; a stiffer environment tends
to select for an infiltrative phenotype.61–63 In vivo, this picture is complicated by the magnetic resonance elastography finding that embedded
cerebral tumor models (e.g. U87) are uniformly less stiff than the surrounding normal brain.64 Our preliminary modeling65 points to the interaction
between the fluid and solid phases in these soft media as a critical determinant of the mechanical stress state in the cerebral tumors that are being
studied.
Mechanical models have previously demonstrated a coupling of interstitial fluid and solid tissue behavior in tumors, including glioma.66–69
One missing element in many previous investigations of the physical properties of cerebral tumors is a relatively complete picture of the fluid
spaces and fluxes in and around the tumor. The dataset herein is unique in its array of noninvasive measures of those properties under both resting and changing conditions. Vascular parameters—blood flow and vascular permeability—plus tissue spaces (interstitial volume fraction, plasma
volume fraction) can be coupled to local stresses through mechanical models. Using poroelastic theory and best estimates of tissue mechanical
properties (stiffness, Poisson ratio, fluid conductivity), measures of spaces and fluxes can be used to estimate mechanical stresses. As noted, these
stresses are important in tumor cellular signaling for replication rate and infiltrative capacity.
By reducing vascular permeability, other aspects of the TME are also altered, including TIFP, interstitial space in and around the tumor,
and exudate flux from the tumor into the surrounding tissue. Avastin administration appears to have an indirect effect on such mechanically
linked properties as solid stress and stiffness in the tumor and its surround. Changes in such parameters as Ktrans, interstitial spaces, plasma
volume, tumor rim exudate flux and hydraulic conductivity following Avastin administration provide insight into physical changes within the
tumor that are important for understanding the microenvironment and its potential for inducing tumor progression. The perturbation in the
physical properties introduced by Avastin will serve as a check on mechanical modeling of in situ tumors and provides assurance that any
model produced will be robust in its description of a cerebral tumor undergoing physical changes. Thus, while an investigation of the shortterm effects of Avastin on the microvasculature of a xenograft tumor might be considered somewhat esoteric in its focus, the larger significance of this investigation is that it provides a unique description of the physical properties of tumor vasculature, both resting and reacting,
in an embedded cerebral tumor.
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C O N CL U S I O N S

The parameters described in this study expand the repertoire of DCE-MRI investigations to encompass several aspects of glioma pathophysiology
that can be measured concurrently, repeatedly and minimally invasively to understand responses to treatments, and to extend the analysis of
those responses to an evaluation of the mechanical state of the tumor and its microenvironment.
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